BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 16061341)

  • 1. HPLC study on stability of pyridoxal isonicotinoyl hydrazone.
    Kovaríková P; Mokrý M; Klimes J; Vávrová K
    J Pharm Biomed Anal; 2006 Jan; 40(1):105-12. PubMed ID: 16061341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the stability of aromatic hydrazones in plasma and related biological material.
    Kovaríková P; Mrkvicková Z; Klimes J
    J Pharm Biomed Anal; 2008 Jun; 47(2):360-70. PubMed ID: 18294799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interaction of pyridoxal isonicotinoyl hydrazone (PIH) and salicylaldehyde isonicotinoyl hydrazone (SIH) with iron.
    Chen YL; Kong X; Xie Y; Hider RC
    J Inorg Biochem; 2018 Mar; 180():194-203. PubMed ID: 29329026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity.
    Simunek T; Sterba M; Popelova O; Kaiserova H; Potacova A; Adamcova M; Mazurova Y; Ponka P; Gersl V
    Hemoglobin; 2008; 32(1-2):207-15. PubMed ID: 18274998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.
    Hershko C; Avramovici-Grisaru S; Link G; Gelfand L; Sarel S
    J Lab Clin Med; 1981 Jul; 98(1):99-108. PubMed ID: 7252329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromatographic methods for the separation of biocompatible iron chelators from their synthetic precursors and iron chelates.
    Kovaríková P; Mokrý M; Klime J; Vávrová K
    J Sep Sci; 2004 Dec; 27(17-18):1503-10. PubMed ID: 15638159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyridoxal isonicotinoyl hydrazone (PIH): a promising new iron chelator.
    Webb J; Vitolo ML
    Birth Defects Orig Artic Ser; 1988; 23(5B):63-70. PubMed ID: 3291971
    [No Abstract]   [Full Text] [Related]  

  • 8. Hydrolysis of pyridoxal isonicotinoyl hydrazone and its analogs.
    Buss JL; Ponka P
    Biochim Biophys Acta; 2003 Jan; 1619(2):177-86. PubMed ID: 12527114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EPR spin trapping and 2-deoxyribose degradation studies of the effect of pyridoxal isonicotinoyl hydrazone (PIH) on *OH formation by the Fenton reaction.
    Hermes-Lima M; Santos NC; Yan J; Andrews M; Schulman HM; Ponka P
    Biochim Biophys Acta; 1999 Feb; 1426(3):475-82. PubMed ID: 10076064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of HPLC-DAD methods for the analysis of two novel iron chelators with potent anti-cancer activity.
    Mrkvicková Z; Kovaríková P; Klimes J; Kalinowski D; Richardson DR
    J Pharm Biomed Anal; 2007 Mar; 43(4):1343-51. PubMed ID: 17166684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone.
    Richardson DR; Milnes K
    Blood; 1997 Apr; 89(8):3025-38. PubMed ID: 9108424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
    Becker E; Richardson DR
    J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyridoxal isonicotinoyl hydrazone and analogues. Study of their stability in acidic, neutral and basic aqueous solutions by ultraviolet-visible spectrophotometry.
    Richardson D; Vitolo LW; Baker E; Webb J
    Biol Met; 1989; 2(2):69-76. PubMed ID: 2642020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LC and LC-MS study of stress decomposition behaviour of isoniazid and establishment of validated stability-indicating assay method.
    Bhutani H; Singh S; Vir S; Bhutani KK; Kumar R; Chakraborti AK; Jindal KC
    J Pharm Biomed Anal; 2007 Mar; 43(4):1213-20. PubMed ID: 17118610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative stress mediates toxicity of pyridoxal isonicotinoyl hydrazone analogs.
    Buss JL; Neuzil J; Ponka P
    Arch Biochem Biophys; 2004 Jan; 421(1):1-9. PubMed ID: 14678779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilise iron from reticulocytes in vitro.
    Ponka P; Richardson DR; Edward JT; Chubb FL
    Can J Physiol Pharmacol; 1994 Jun; 72(6):659-66. PubMed ID: 7954097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process.
    Richardson DR
    Biochim Biophys Acta; 1997 May; 1320(1):45-57. PubMed ID: 9186779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
    Richardson DR; Ponka P
    J Lab Clin Med; 1994 Nov; 124(5):660-71. PubMed ID: 7964124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties.
    Buss JL; Neuzil J; Gellert N; Weber C; Ponka P
    Biochem Pharmacol; 2003 Jan; 65(2):161-72. PubMed ID: 12504792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPLC determination of a novel aroylhydrazone iron chelator (o-108) in rabbit plasma and its application to a pilot pharmacokinetic study.
    Kovaríková P; Klimes J; Sterba M; Popelová O; Gersl V; Ponka P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jul; 838(2):107-12. PubMed ID: 16725389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.